These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19487289)

  • 1. AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects.
    Davies NJ; Hayden RE; Simpson PJ; Birtwistle J; Mayer K; Ride JP; Bunce CM
    Cancer Res; 2009 Jun; 69(11):4769-75. PubMed ID: 19487289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New enzymatic assay for the AKR1C enzymes.
    Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
    Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria.
    Rotem R; Heyfets A; Fingrut O; Blickstein D; Shaklai M; Flescher E
    Cancer Res; 2005 Mar; 65(5):1984-93. PubMed ID: 15753398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methyl jasmonate: a plant stress hormone as an anti-cancer drug.
    Cohen S; Flescher E
    Phytochemistry; 2009 Sep; 70(13-14):1600-9. PubMed ID: 19660769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
    Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
    Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldo-keto reductase 1C subfamily genes in skin are UV-inducible: possible role in keratinocytes survival.
    Marín YE; Seiberg M; Lin CB
    Exp Dermatol; 2009 Jul; 18(7):611-8. PubMed ID: 19320734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3.
    Traven K; Sinreih M; Stojan J; Seršen S; Kljun J; Bezenšek J; Stanovnik B; Turel I; Rižner TL
    Chem Biol Interact; 2015 Jun; 234():349-59. PubMed ID: 25446855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
    Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
    Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
    Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase.
    Goldin N; Arzoine L; Heyfets A; Israelson A; Zaslavsky Z; Bravman T; Bronner V; Notcovich A; Shoshan-Barmatz V; Flescher E
    Oncogene; 2008 Aug; 27(34):4636-43. PubMed ID: 18408762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
    Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.
    Bauman DR; Rudnick SI; Szewczuk LM; Jin Y; Gopishetty S; Penning TM
    Mol Pharmacol; 2005 Jan; 67(1):60-8. PubMed ID: 15475569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-cancer activities of jasmonates.
    Raviv Z; Cohen S; Reischer-Pelech D
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):275-85. PubMed ID: 23196641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
    Khanim F; Davies N; Veliça P; Hayden R; Ride J; Pararasa C; Chong MG; Gunther U; Veerapen N; Winn P; Farmer R; Trivier E; Rigoreau L; Drayson M; Bunce C
    Br J Cancer; 2014 Mar; 110(6):1506-16. PubMed ID: 24569460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jasmonates in cancer therapy.
    Flescher E
    Cancer Lett; 2007 Jan; 245(1-2):1-10. PubMed ID: 16600475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural jasmonates of different structures suppress the growth of human neuroblastoma cell line SH-SY5Y and its mechanisms.
    Tong QS; Jiang GS; Zheng LD; Tang ST; Cai JB; Liu Y; Zeng FQ; Dong JH
    Acta Pharmacol Sin; 2008 Jul; 29(7):861-9. PubMed ID: 18565287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
    Beranič N; Gobec S; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Jasmonates induce nonapoptotic death in high-resistance mutant p53-expressing B-lymphoma cells.
    Fingrut O; Reischer D; Rotem R; Goldin N; Altboum I; Zan-Bar I; Flescher E
    Br J Pharmacol; 2005 Nov; 146(6):800-8. PubMed ID: 16170329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
    Birtwistle J; Hayden RE; Khanim FL; Green RM; Pearce C; Davies NJ; Wake N; Schrewe H; Ride JP; Chipman JK; Bunce CM
    Mutat Res; 2009 Mar; 662(1-2):67-74. PubMed ID: 19162045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jasmonates--a new family of anti-cancer agents.
    Flescher E
    Anticancer Drugs; 2005 Oct; 16(9):911-6. PubMed ID: 16162967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.